The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...
Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...
The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback